Protalix BioTherapeutics Inc

Visual Financials
Company Name: Protalix BioTherapeutics Inc
Ticker Symbol: PLX
CIK Number: 0001006281
WWW Address: http://www.protalix.com
CEO: Moshe Manor
No. of Employees: 223
Common Issue Type: CS
Business Description:Protalix BioTherapeutics, Inc. is a biopharmaceutical company engaged in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx® protein expression system.

 
Industry Information: DRUGS - Biotechnology [more like this]
 Price  Day Change  Bid  Ask  Open  High  Low  Volume 
 0.31 Unchanged 0.0 - -  0.44 0.29 988484
 Market Cap (mil) Shares Outstanding (mil) Beta EPS DPS P/E Yield 52-Wks-Range
 30.9 99.8 0.00 0.61 0.00 1.0 0.0 1.05 - 0.29
KEY FIGURES (Latest Twelve Months - LTM)
Yesterday's Close0.31$
PE Ratio - LTM1.0
Market Capitalisation30.9mil
Latest Shares Outstanding99.8mil
Earnings pS (EPS)0.61$
Dividend pS (DPS)0.00¢
Dividend Yield0.0%
Dividend Payout Ratio%
Revenue per Employee19,570$
Effective Tax Rate0.0%
Float83.1mil
Float as % of Shares Outstanding0.8%
Foreign Salesmil
Domestic Salesmil
Selling, General & Adm/tive (SG&A) as % of Revenue1.70%
Research & Devlopment (R&D) as % of Revenue4.60%
Gross Profit Margin83.3%
EBITDA Margin-485.3%
Pre-Tax Profit Margin0.0%
Assets Turnover5.0%
Return on Assets (ROA)66.1%
Return on Equity (ROE)0.0%
Return on Capital Invested (ROCI)0.0%
Current Ratio7.6
Leverage Ratio (Assets/Equity)8.9
Interest Cover-6.3
Total Debt/Equity (Gearing Ratio)6.63
LT Debt/Total Capital87.0%
Working Capital pS0.75$
Cash pS0.00$
Book-Value pS-0.08$
Tangible Book-Value pS0.11$
Cash Flow pS-0.35$
Free Cash Flow pS-0.35$
KEY FIGURES (LTM): Price info
Price/Book Ratio-7.13
Price/Tangible Book Ratio0.00
Price/Cash Flow-1.7
Price/Free Cash Flow-1.6
P/E as % of Industry Group0.0%
P/E as % of Sector Segment0.0%
 
Balance Sheet (at a glance) in Millions
DIVIDEND INFO
Type of Payment-
Dividend Rate0.00
Current Dividend Yield0.0
5-Y Average Dividend Yield0.0
Payout Ratio0.0
5-Y Average Payout Ratio0.0
Share price performance previous 3 years

Share price performance intraday

 
PRICE/VOLUMEHighLowClose% Price Chg% Price Chg vs. Mkt.Avg. Daily VolTotal Vol
1 Week---9.7111,242,56811,592,328
4 Weeks0.650.290.4330.726751,58015,031,615
13 Weeks0.650.290.60-6.7-7290,08318,855,428
26 Weeks0.830.290.79-29.2-34201,47926,192,322
52 Weeks1.050.291.00-44.1-49182,27946,481,366
YTD1.020.29--44.6-54145,07634,092,992
Moving Average5-Days10-Days10-Weeks30-Weeks200-DaysBeta (60-Mnth)Beta (36-Mnth)
0.500.500.510.620.680.000.00
 
GROWTH RATES5-Year
Growh
R² of 5-Year Growth3-Year
Growth
Revenue-0.080.0-0.50
Income0.0
Dividend0.0
Capital SpendingNA
R&D16.26NA5.85
Normalized Inc.0.00NA0.00
 
CHANGESYTD vs.
Last YTD
Curr Qtr vs.
Qtr 1-Yr ago
Annual vs.
Last Annual
Revenue %-4.3-4.3315.8
Earnings %0.00.00.0
EPS %-100.0-100.0-100.0
EPS $-0.12-0.12-0.56
 
SOLVENCY RATIOS
SHORT-TERM SOLVENCY RATIOS (LIQUIDITY)
Net Working Capital Ratio76.75
Current Ratio7.6
Quick Ratio (Acid Test)6.8
Liquidity Ratio (Cash)13.60
Receivables Turnover0.0
Average Collection Period
Working Capital/Equity686.5
Working Capital pS0.75
Cash-Flow pS-0.26
Free Cash-Flow pS-0.26
FINANCIAL STRUCTURE RATIOS
Altman's Z-Score Ratio1.35
Financial Leverage Ratio (Assets/Equity)6.6
Debt Ratio74.1
Total Debt/Equity (Gearing Ratio)6.63
LT Debt/Equity6.63
LT Debt/Capital Invested90.6
LT Debt/Total Liabilities100.0
Interest Cover-6.3
Interest/Capital Invested4.34
 
VALUATION RATIOS
MULTIPLES
PQ Ratio0.00
Tobin's Q Ratio0.58
Current P/E Ratio - LTM1.00
Enterprise Value (EV)/EBITDA0.45
Enterprise Value (EV)/Free Cash Flow3.70
Dividend Yield0.0
Price/Tangible Book Ratio - LTM0.00
Price/Book Ratio - LTM-7.13
Price/Cash Flow Ratio-1.7
Price/Free Cash Flow Ratio - LTM-1.6
Price/Sales Ratio0.00
P/E Ratio (1 month ago) - LTM0.0
P/E Ratio (26 weeks ago) - LTM25.3
P/E Ratio (52 weeks ago) - LTM15.3
5-Y High P/E Ratio-22.0
5-Y Low P/E Ratio-1.6
5-Y Average P/E Ratio0.0
Current P/E Ratio as % of 5-Y Average P/E
P/E as % of Industry Group0.0
P/E as % of Sector Segment0.0
Current 12 Month Normalized P/E Ratio - LTM0.0
PER SHARE FIGURES
LT Debt pS0.80
Current Liabilities pS0.12
Tangible Book Value pS - LTM0.11
Book Value pS - LTM-0.08
Capital Invested pS0.83
Cash pS - LTM0.00
Cash Flow pS - LTM-0.35
Free Cash Flow pS - LTM-0.35
Earnings pS (EPS)0.61
 
OPERATING RATIOS
PROFITABILITY RATIOS
Free Cash Flow Margin-567.09
Free Cash Flow Margin 5YEAR AVG-280.26
Net Profit Margin-6.3
Net Profit Margin - 5YEAR AVRG.0.8
Equity Productivity0.40
Return on Equity (ROE)0.0
Return on Equity (ROE) - 5YEAR AVRG.
Capital Invested Productivity0.05
Return on Capital Invested (ROCI)0.0
Return on Capital Invested (ROCI) - 5YEAR AVRG.
Assets Productivity0.00
Return on Assets (ROA)0.7
Return on Assets (ROA) - 5YEAR AVRG.-0.1
Gross Profit Margin83.3
Gross Profit Margin - 5YEAR AVRG.0.5
EBITDA Margin - LTM-485.3
EBIT Margin - LTM-539.6
Pre-Tax Profit Margin0.0
Pre-Tax Profit Margin - 5YEAR AVRG.
Effective Tax Rate0.0
Effective Tax Rate - 5YEAR AVRG.0.0
EFFICIENCY RATIOS
Cash Conversion Cycle
Revenue per Employee19,570
Net Income per Employee260,256
Average Collection Period
Receivables Turnover0.0
Day's Inventory Turnover Ratio
Inventory Turnover0.1
Inventory/Sales132.1
Accounts Payble/Sales83.16
Assets/Revenue0.00
Net Working Capital Turnover0.06
Fixed Assets Turnover0.38
Total Assets Turnover0.0
Revenue per $ Cash0.06
Revenue per $ Plant0.45
Revenue per $ Common Equity0.40
Revenue per $ Capital Invested0.05
Selling, General & Adm/tive (SG&A) as % of Revenue166.8
SG&A Expense as % of Revenue - 5YEAR AVRG.0.0
Research & Devlopment (R&D) as % of Revenue458.9
R&D Expense as % of Revenue - 5YEAR AVRG.458.9

  


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.